A time-resolved proteomic and prognostic map of COVID-19

  • Vadim Demichev (Shared first author)
  • Pinkus Tober-Lau (Shared first author)
  • Oliver Lemke
  • Tatiana Nazarenko
  • Charlotte Thibeault
  • Harry Whitwell
  • Annika Röhl
  • Anja Freiwald
  • Lukasz Szyrwiel
  • Daniela Ludwig
  • Clara Correia-Melo
  • Simran Kaur Aulakh
  • Elisa T Helbig
  • Paula Stubbemann
  • Lena J Lippert
  • Nana-Maria Grüning
  • Oleg Blyuss
  • Spyros Vernardis
  • Matthew White
  • Christoph B Messner
  • Michael Joannidis
  • Thomas Sonnweber
  • Sebastian J Klein
  • Alex Pizzini
  • Yvonne Wohlfarter
  • Sabina Sahanic
  • Richard Hilbe
  • Benedikt Schaefer
  • Sonja Wagner
  • Mirja Mittermaier
  • Felix Machleidt
  • Carmen Garcia
  • Christoph Ruwwe-Glösenkamp
  • Tilman Lingscheid
  • Laure Bosquillon de Jarcy
  • Miriam S Stegemann
  • Moritz Pfeiffer
  • Linda Jürgens
  • Sophy Denker
  • Daniel Zickler
  • Philipp Enghard
  • Aleksej Zelezniak
  • Archie Campbell
  • Caroline Hayward
  • David J Porteous
  • Riccardo E Marioni
  • Alexander Uhrig
  • Holger Müller-Redetzky
  • Heinz Zoller
  • Judith Löffler-Ragg
  • Markus A Keller
  • Ivan Tancevski
  • John F Timms
  • Alexey Zaikin
  • Stefan Hippenstiel
  • Michael Ramharter
  • Martin Witzenrath
  • Norbert Suttorp
  • Kathryn Lilley
  • Michael Mülleder
  • Leif Erik Sander
  • Markus Ralser
  • Florian Kurth
  • Pa-COVID Study Group

Related Research units

Abstract

COVID-19 is highly variable in its clinical presentation, ranging from asymptomatic infection to severe organ damage and death. We characterized the time-dependent progression of the disease in 139 COVID-19 inpatients by measuring 86 accredited diagnostic parameters, such as blood cell counts and enzyme activities, as well as untargeted plasma proteomes at 687 sampling points. We report an initial spike in a systemic inflammatory response, which is gradually alleviated and followed by a protein signature indicative of tissue repair, metabolic reconstitution, and immunomodulation. We identify prognostic marker signatures for devising risk-adapted treatment strategies and use machine learning to classify therapeutic needs. We show that the machine learning models based on the proteome are transferable to an independent cohort. Our study presents a map linking routinely used clinical diagnostic parameters to plasma proteomes and their dynamics in an infectious disease.

Bibliographical data

Original languageEnglish
ISSN2405-4712
DOIs
Publication statusPublished - 18.08.2021

Comment Deanary

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

PubMed 34139154